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Abstract 
The Sigma-1 receptor (S1R) is an important pharmaceutical target that has been linked to several 
neurological diseases and drug addiction. It has been proposed that multimerization of S1R is 
important for attenuating its interactions with the dopamine transporter (DAT) and that S1R 
agonists promote dissociation to a monomeric form necessary for DAT interaction. This project 
aims to assess the role of the N-terminal transmembrane domain in oligomerization and binding 
activity of the mammalian Sigma-1 receptor (S1R). N-terminal truncations lacking the 
transmembrane domain and the E102Q variant, which displays altered activity and cellular 
localization, were expressed, purified in order to determine their contributions to the overall 
structure.  
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Introduction 
In normal neuronal communication, neurotransmitters are released by the presynaptic neuron and 
bind to receptors on the postsynaptic neuron thereby altering the permeability of the membrane 
or intracellular signaling pathways. Following release from the presynaptic terminals, the 
neurotransmitter is degraded or absorbed back into the presynaptic neuron. The dopamine 
transporter (DAT) carries dopamine back into the dopamine nerve terminals. Addictive drugs, 
including cocaine and methamphetamine4, block the action of DAT. These drugs bind with a 
high affinity to the DAT, markedly increasing the dopamine concentration in the synapse. It is 
proposed that the sigma-1 receptor (S1R) effectively regulates the flow of dopamine as it binds 
to DAT.  
The S1R is a therapeutic target for neurodegenerative conditions, several psychiatric 
diseases and neurodegenerative diseases, such as Alzheimer’s Disease and amyotrophic lateral 
sclerosis (ALS)2. It is also a therapeutic target for cancer due to its neurotransmitter binding 
properties1. Some forms of ALS, in particular with a juvenile onset, has been linked to the 
mutations of S1R, which makes the S1R a major therapeutic target to help create better 
medications with higher binding specifity1. ALS is familial in about 10% of all ALS diagnoses. 
SOD1 mutation accounting for the most common (approximately 20%) cause of familial ALS 
cases. The SOD1 gene codes Cu/Zn superoxide dismutase, which is an enzyme1. A mutation of 
this gene would then impact the structure of the enzyme and change its abilities to function 
normally. 
6 
 
 
In 2016 the structure of the trimeric form 
of the S1R, which is the naturally 
occurring form, was determined by X-
Ray crystallography. In Figure 1, the 
structure has three transmembrane 
domains (Figure 1), whereas, previous 
models predicted that there would be 
multiple transmembrane regions within each subunit. This means that the predicted model’s 
active region, the site where ligands bind, is slightly different than what is actually present. This 
model contains three subunits with each color referring to a single monomer of the S1R One of 
the main aspects of my research project is to determine the structure of the monomeric form to 
see if the active site structure changes and how the monomer functions.  
  
The receptor binds to chemical 
ligands differently depending on whether 
the ligand is an agonist or antagonist, as 
shown in Figure 25. A ligand that does 
not promote activity then would act as an 
antagonist and increase S1R’s stability in 
the multimeric form. However, if the 
ligand promotes activity, an agonist, then the receptor is proposed to have a decreased stability in 
the trimeric form and favor the monomeric form. This is important as the receptor binds to DAT, 
Figure 1: Above is the structure of the trimer form of 
the S1R.6 
Figure 2: This figure shows the hypothesized binding of 
the S1R when agonists or antagonists are present. When 
an agonist is present then it is more likely to be in the 
monomer form.5 
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a dopamine transporter. Currently it is hypothesized that the S1R monomer would bind with 
DAT and lock it in an outward facing confirmation5. Cocaine and Methamphetamine would still 
be able to bind with DAT and, since DAT is locked in an outward facing confirmation, is 
prevented from releasing the drug5. An outward facing DAT means that the substance bound to 
DAT cannot be transported into the brain cell, due to being outside of the cell membrane. This 
prevents the regulation of dopamine and would thus increase the dopamine effect.  The inward 
facing DAT can transport its substance into the neuron5. This suggests that the monomeric form 
of S1R is the active form and the trimeric form is the inactive form of the receptor, due to the 
monomeric form binding with the DAT and preventing DAT moving from the outward-facing to 
inward-facing conformation.       
  
To attempt to produce the 
monomeric form of the S1R I will be 
using truncated versions of the receptor 
that preliminary data show naturally 
forms the monomer (Fig. 3). 
Preliminary data provided by Dr. Hong 
(Department of Pharmaceutical Sciences, Butler University) shows that removing the 
transmembrane domain decreases the S1R’s ability to form the trimeric form of the S1R. The 
truncations I made are Δ1-10 and Δ1-36, which truncate the first ten and 36 amino acids of the 
N-terminus respectively. ΔV7 and ΔE3 (deletion of amino acids 119-149 of N-terminus) are both 
internal deletions, which also have a decreased ability to form the trimeric form of S1R.  The 
reason behind this trend is still unknown but is believed to be that the transmembrane domain is 
Figure 3: Shows the different S1R that are being used 
for this experiment.   
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interacting with another part of the S1R to create a stable trimer. These proteins were over-
expressed in E. coli as a C-terminal fusion to the Ruby Fluorescent Protein.    
Another component of my research is to determine the structure and activity of a 
naturally occurring mutant form of the S1R. The specific mutation is a glutamic acid residue to a 
glutamine residue on residue 102 (E102Q) (Fig. 3), which changes the intermolecular 
interactions that can occur.  
 
The glutamine mutation 
provides an extra hydrogen bond 
donor and loses the negative 
charge at physiological pH. This 
changes the charge of the protein 
as it loses negative character. This 
change would also affect the 
intermolecular forces of the 
protein as negative atoms 
interact differently than positive 
atoms. Using the wild-type model, the glutamic acid residue at 102 is making hydrogen bonds 
Figure 5: The PyMOL structure of S1R with the hydrogen bonds that 
can form with E102 
Figure 4: shows the 
structures of glutamic acid 
and glutamine to 
demonstrate the change in 
structure. 
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with surrounding residues, Tyr173, Phe37, and Val36 (Fig. 5). The mutation would serve as a 
hydrogen bond donor to the surrounding residues. This means that a hydrogen bond could be 
made with the oxygen of the Tyr173 and the oxygen of Phe-37 (Figure 5).  However, potential 
new interactions will be revealed when the protein is crystallized and the structure is determined.  
 In essence, the importance of the S1R is that it can bind to many different ligands, 
including DAT when addictive drugs, such as Cocaine and Methamphetamine are bound to 
DAT. The S1R is a pharmaceutical target since it is a brain receptor that is able to bind with 
ligands with high affinity. This would allow for potential new drugs for neurodegenerative 
diseases to be created.  The S1R has also been linked to many diseases due to mutations in the 
receptor, like the 102 residue change from glutamic acid to glutamine1. Understanding more 
about those mutations will help those diseases receive better treatments due to the causes of the 
diseases being better understood.  
Materials and Methods 
 Primer Design 
 Primers were designed so that Polymerase Chain (PCR) reaction can be used to replicate 
the S1R constructs. The software A plasmid Editor (ApE) was used to design the primer. The 
primer consisted of the first 20-22 nucleotides of the sequence we were trying to replicate. The 
exact number of nucleotides in the primer was determined by attempting to create a DNA 
sequence with a Tm between 52-55°C so that it can be stable for the PCR reaction, which 
requires heat. The wild type, E102Q mutant, ΔE3 the 5’ primer was 
GGATCCATGCAGTGGGCCGTG. The 3’ primer was designed for the wild-type and all 
mutants, CTCGAGTCAAGGGTCCTGGCC. The Δ36 S1R and the 5’ primer was 
AGAACCAGGATCCTTCCAGCGCGAAGAG. The Δ10 5’ primer was 
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AGAACCAGGATCCTGGGCCGCGCTG. The V7 truncation 5’ primer was 
GGATCCATGCGGGTGGCTGG. The 3’ primer was the same as the truncations used are all 
either internal or of the N-terminus, which only truncates one side of the DNA strand. 
PCR of Templates 
Polymerase Chain Reaction (PCR) was used to amplify each of the S1R construct’s 
DNA. Thermopol 1x Buffer (20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 
0.1% Triton®-X-100, pH 8.8 @ 25 °C), 0.4μM DNTP, 2.5 of Pfu, 1μL of DNA template, 26nM 
3’ primer, 26nM 5’ primer for a final volume of 50 μL. The reaction was run in a Biorad my 
cycler thermo cycler. Each type of Sigma-1 Receptor had the same PCR protocol. The reactions 
were run at 95°C for 1 minute. Then cycled at 95°C for 30 seconds, 52°C for 30 seconds, 72°C 
for 2 minutes and this cycle was repeated five times. The second stage of cycling was 95°C for 
30 seconds then at 57°C for 30 seconds then at 72°C for 2 minutes and repeated 25 times. Then 
the mixture was heated to 72°C for 10 minutes and then cooled to 4°C until taken out of the 
machine. 
 PCR Cleanup 
 After PCR reactions and restriction digests, a PCR protocol cleanup was used to ensure 
the DNA was purified. 50 μL of DNA was added to a microfuge tube. 5 volumes of DF buffer 
(20 mM Tris-HCl,10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4 pH 8.8@25°C) were also 
added to the microfuge tube and the tube was then vortexed to allow the buffer and DNA to mix. 
The mixture was then transferred to a column and run in the microfuge for 30 seconds at 14000 
16000 g. Then 600μL of wash buffer was added and then the column was run for 30 seconds at 
14-16xg. The eluted buffer was removed from the collection tube and then the column was run 
on a microfuge for 3 minutes at 14000-16000g. 30-50μL of water was added and the mixture was 
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left to sit for two minutes. Then the mixture was run on the centrifuge for 2 minutes at 14000-
16000 g to elute.  
 Restriction Digest 
 The S1R and pET-28 DNA were digested so that the S1R could be inserted into the new 
plasmid. 1x Buffer (10 mM NaCl, 5 mM Tris-HCl, 1 mM MgCl2, 10 µg/ml BSA, pH 
7.9@25°C), 1μL BamHI, 1μL XhoI, in a final volume of 60μL. The mixture was then placed in 
37°C water bath for two hours. The digestion was then purified using the PCR cleanup protocol. 
When digesting the pET-28 plasmid, an extra step to purify was needed. After the restriction 
digestion, the mixture was run on an agarose gel and the lower band was cut out. The higher 
band was placed, of expected of 6025 nucleotides, into a microfuge tube and heated in a 60°C 
water bath until the solid agarose became liquid. All gel electrophoresis ran at a constant voltage 
of 100V for one hour. 
Ligation 
 Ligation was used to fuse the pET-28-Ruby plasmid to the S1R constructs. 100ng of 
pET-28 plasmid and 83ng of S1R insert DNA were mixed together with 1x T4 DNA Ligase 
buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT pH 7.5@25°C), 1 μL of 
Ligase, and water for a final column amount of 20μL. This reaction was allowed to go overnight 
at room temperature and then was transformed into DH5α E.coli cells. 
Transformation of DH5α 
 DNA was transformed using standard transformation protocol. First, 10μL of ligation 
mixture were added to 100μL of E.coli cells and the mixture was placed into an ice bath for an 
hour. After the hour, the mixtures were heat shocked at 42°C for 45 seconds, then placed back in 
an ice bath for 2-3 minutes. The mixture was then transferred to a 1mL of LB and placed in a 
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shaker at 37°C for 45 minutes. The cells were pelleted. Then the pellets and were re-suspended 
in about 100μL of LB and was plated on LB-Kan (Lysogeny Broth with 40μg/mL Kanamycin 
antibiotic) plates and incubated overnight at 37°C.     
Minicultures and Minipreps of Ligation 
  Minicultures were made so that the ligated pet-28-Ruby S1R variant fusion could 
be purified for each p-Ruby WT, E102Q, ΔE3, V7 Δ10 and Δ36. Colonies of each S1R variants 
were extracted from the DH5α plate and placed into a 3mL culture of Lysogeny Broth (LB), 
which was then placed in a shaker at 37°C, shaking at a constant rate of 225rpm. Then the 
culture was transferred to microfuge tubes. 1.5mL of culture was transferred and then spun at 14-
16xg for 1 minute. The supernatant was discarded and this process was repeated as needed. Then 
200μL of PD1 buffer was used to resuspend the cells. 200μL of PD2 buffer was added and the 
solution was inverted ten times to mix. The solution sat or at least two minutes, but no longer 
than five. 300μL of PD3 buffer was added and inverted ten times to mix. This solution was 
centrifuged for 3 minutes at 14000-16000 g. The supernatant was extracted from the microfuge 
and transferred to a PD column. The column was centrifuged for 3 minutes at 14000-16000 g. 
Then 400μL of W1 buffer was added and was centrifuged for 30 seconds at 14000-16000 g. 
600μL of wash buffer was added. The column was centrifuged for 30 seconds at 14000-16000 g. 
The flow through in the collection tube was discarded and the column was centrifuged for 
another three minutes at 14000-16000 g. Then 50μL of water was added to the column and the 
solution was allowed to sit for at least two minutes. Then the solution was eluted by centrifuging 
the solution for two minutes at 14000-16000 g. 
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 Restriction Digestion 
Another way to see if the S1R DNA cloned correctly was by performing an analytical 
digest. To do this, SacI and BamH I were used. The pET28 vector that was used to clone the S1R 
DNA was originally infused to Shrm DNA. The pET-28-Ruby-Shrm plasmid was thus used as a 
positive control. The restriction enzymes that were chosen cleave the two different constructs 
differently, which can be seen in figure 6 below. For the restriction digest 1x Cutsmart Buffer (5 
mM Potassium Acetate, 2 mM Tris-acetate, 1 mM Magnesium Acetate, 10 µg/ml BSA pH 
7.9@25°C) 3μL of plasmid DNA, 0.5μL of SacI, 0.5μL of BamHI, and water for a final volume 
of 10μL were mixed together. The mixture was placed in a 37° water bath for an hour. After the 
hour, 2μL of purple loading dye was loaded into each sample and then loaded into the gel 
electrophoresis. The gel ran for an hour at 100V and then was photographed.  
 
Figure 6: Shows the plasmid map for the pET-28-Ruby-S1R  with restriction enzyme sites, SacI and 
BamHI labeled. 
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DNA Sequencing 
The S1R DNA variants that showed positive results from the restriction 
digest were sequenced. 5μL of S1R variant DNA, 1μL T7 terminator primer 
(served as the 3’ primer), 1μL Ruby forward primer (served as the 5’ primer) with 
3μL of water. This was sent to Genewiz, where the S1R DNA variants were 
sequenced. The Ruby forward primer was GTTCGTAGTACAACGCG. The T7 
terminator primer was TAATACGACTCGCTATAGGG. 
Protein Expression in LoBSTR 
10μL of the S1R variant DNA that was sequenced were added to 100μL of E.coli cells 
and the mixture was placed into an ice bath for an hour. After the hour, the mixtures were heat 
shocked at 42°C for 45 seconds. Then the mixtures were placed back in an ice bath for 2-3 
minutes. The mixture was then transferred to a 1mL culture of Lysogeny Broth (LB) and placed 
in a shaker at 37°C for 45 minutes to an hour. 100μL of transformation culture was extracted and 
plated on LB-KanCam (Lysogeny Broth with 40μg/mL Kanamycin and 30μg/mL M 
Chloramphenicol antibiotics) plates and incubated overnight at 37°C.   
 The WT, E102Q, and Δ36 S1R variants were transformed into E. coli LOBSTR in LB 
with 4μg kanamycin and 3μg chloramphenicol antibiotics. From the plates, a colony on the plate 
was then picked and placed in 3mL of LB with 120μg Kan and 90μg Cam antibiotics and then 
this mixture was left to grow overnight at 37°C shaking at a constant rate of 225rpm. Then one 
milliliter of this overnight culture was added to a 1L culture of LB with 4mg kanamycin and 3mg 
mM chloramphenicol and was placed in a shaker at 20°C with a constant shaking rate of 225 
rpm. IPTG was added when the mid-log phase was reached (Absorbance is equal to 0.6 to 0.8) 
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and then allowed to grow to saturation. The cells were pelleted by running the JA 20 rotor at 
5000rpm for 10 minutes at 4°C. The excess media was discarded and then the pellets were 
resuspended in PBS using a conical tube. The resuspended cells were centrifuged at 4000rpm for 
10 minutes at 4°C using rotor JA 12, the excess PBS was discarded.  
 Protein Purification 
 The cells were re-suspended in an S1R solubilizing buffer (20 mM Tris–HCl, pH 8.0, 
containing 300 mM NaCl, 1 mM 2- mercaptoethanol, and 0.25 mM phenylmethylsulfonyl 
fluoride) and then poured into the homogenizer6. The cells were lysed by pressure between 
20,000 and 23,000 bar and were cycled through until the mixture for 3-5 minutes. The lysate was 
then centrifuged at 40,000g for 20 minutes. The supernatant was decanted into another conical 
tube. 1mL of Ni-NTA resin was then added to the supernatant and then allowed to mix for 15 
minutes. The mixture was poured into a Ni-NTA affinity column and fractions were collected by 
gravity. The first step of the column was to allow the supernatant to flow through then the 
column was washed with 50mM Imidazole (1x PBS pH=7.4) was used to wash and the bound 
protein was eluted with 500mM Imidazole (1x PBS pH=7.4). Fractions of the flow through, 
wash, and elution were collected to be analyzed by SDS-gel electrophoresis.   
 Detergent Trials  
 
 After the Ni-NTA affinity column, it was determined that the protein was not soluble and 
remained bound to the cell membrane. To extract the protein detergents were used. A series of 
detergents were used in order to see which mixture maximized the extraction of the WT, E102Q, 
and Δ36 variants of the S1R. To solubilize the S1R in the E. coli cells, four detergents Triton X-
100, GDN (glyco-diosgenin), DDM (n-Dodecyl β-D-maltoside), and Deoxycholate. Triton was 
used individually and mixed with each of the other three detergents. The concentration of Triton 
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X-100 was varied to determine which concentration of Triton maximized the extraction of each 
of the variants of S1R. These trials used 100μL of S1R to test which conditions yielded the 
highest extraction rates. The detergents were mixed with the S1R overnight on a rocker. Then the 
samples were run on SDS gels to test if S1R was extracted.    
Results and Discussion 
 
Figure 7. PCR products for the Wild Type(1), Mutant(2), and V7 truncated (3) S1R.  
 
Figure 6 shows that the correct PCR products were obtained for the Wild type (WT), 
E102Q mutant, and V7 truncation S1R variants.  The expected size of the WT and E102Q 
variants was 672 nucleotides. The expected size of the V7 truncation was 387 nucleotides, 
confirming that PCR amplification of the wild type and variants were successful.  
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Figure 8. Analytical Restriction Digest of pET28-Ruby-S1R-TEV.  
 
The analytical digest that was used in order to determine if the ligation and cloning 
process was successful is shown in figure 7. Lanes 1-3 are WT, 4-11 are E102Q, and 12-19 are 
V7 truncations. Lane 20 is a pET28-Ruby-Shrm control. This restriction digest using SacI and 
BamHI was done to test the constructs we made by seeing if the correct bands appeared in the 
gel. For the WT and E102Q construct the expected sizes of the bands were 6061 and 642 
nucleotides. Lane 2, which was a WT lane, produced two bands, but one band was above the 750 
nucleotide marker, which indicated that the clone was negative. Lane 7 and 12 also indicated 
negative as they produced two bands, but neither band was of the correct size. The V7 truncation 
mutation would produce two bands with the sizes of 6061 and 342 nucleotides. If the ligation 
was unsuccessful then shrm would be fused to p-Ruby, which would have different expected 
bands at 5862, 324, 213, 191, 42, and 24 nucleotides. This suggests that all other lanes were 
positive as the correct size bands were produced in the gel. 
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Figure 9. The DNA sequencing data of Wild Type and E102Q Mutant  
 
The WT and E102Q variants were both sequenced. The codon that translates into glutamate is 
GAG and the codon that translates into glutamine is CAG. The sequencing also shows that the point 
mutation was done correctly as the 390th nucleotide was changed from a G to a C, which represents the 
change from E to Q on the 102nd amino acid.    
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Figure 10. The DNA sequencing data for the V7 truncation 
 
Figure 9 shows the sequencing data for the V7 truncation. The expected DNA sequence is 
displayed on the top line and sequencing data is on the bottom line. This sequencing data for the V7 
truncation shows that there were extra base pairs than what was expected. This was the result of using a 
primer that did not target the correct part of the receptor and created a different truncation. A problem 
with this truncation was that it created a new stop codon before the end of the receptor and, thus, would 
not form the entire receptor. 
 
 
Figure 11. PCR products for the Δ10(1), Δ36(2), and ΔE3(3) (respectively on the gel to the right).  
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The PCR products of the Δ10, Δ36, and ΔE3 were run on an Agarose gel. The expected 
sizes are Δ10= 642 nucleotides, Δ36=564 nucleotides, and the ΔE3=582 nucleotides. Both the 
Δ10 and the Δ36 variants were positive based on expected size. The ΔE3 variant is an internal 
truncation, which was also cloned correctly based on size. The E3 variant was not used in further 
experiments as internal truncations can be more unstable and both the E3 truncation and the Δ36 
truncation supported the protein to be a monomer.  
 
Figure 12. Restriction Digest of Δ36 and Δ10 S1R variants 
Lanes 1-8 are Δ36 S1R fusions and Lanes 9-12 are Δ10 S1R fusions. Lane 13 is a 
pET28-Shrm control lane. The expected sizes of the bands for the Δ10 are 6061 and 612. The 
expected sizes for the Δ36 are 6061 and 534. This agarose gel shows that lanes 9-12 failed as 
they have bands higher than expected, which means that the cloning process for those samples 
failed. Lanes 1-8 all showed positive results and was then used in other experiments. The lower 
band of expected size 534 was on the gel, but appeared very faint and did not appear on the 
photo. Due to the all of the Δ10 samples failing to clone, it was excluded from further studies as 
the Δ36 and Δ10 both had preliminary data that showed that both were naturally occurring in the 
monomeric form of the S1R rather than the expected trimeric form. 
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Figure 13. SDS Gel of WT S1R Protein 
 
Purity was tested after initial Ni-NTA affinity chromatography to ensure no S1R eluted in 
the first wash. The first lane was re-suspended protein pellet with the next three lanes being the 
flow through (2), wash (3), and elution (4) stages of the Ni-NTA chromatography. This shows 
that no S1R eluted, but rather Ruby fluorescent protein severed from the S1R during expression.   
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Figure 14. SDS Gel of WT, E102Q, and Δ36 S1R protein 
This figure shows the SDS gel for the WT (1), E102Q (2), and Δ36 (3) in the pellet after 
the lysed cells had been centrifuged. This shows that the S1R was highly expressed in the pellet 
for each of the three S1R and that detergents would be needed to extract the protein from the 
pellets for each of the three S1R variants. Meaning that the protein is not soluble and is likely 
bound to the cell membrane material. This property makes sense as the S1R is a transmembrane 
protein and does interact with the cell membrane to perform its functions. 
 25 kDa 
20 kDa 
48 kDa 
63 kDa 
75 kDa 
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Conclusion and Future Direction 
 Through these experiments, the S1R was able to be cloned in the wild type, E102Q, and 
Δ36 variants with a fusion to pET-28. This was confirmed using sequencing data and restriction 
digestion. Initial results suggest that the cloning of the Δ10 failed and that we focused on the 
purification of the wild type, E102Q, Δ36 variants. Initial results suggest that the ΔE3 variant 
was cloned successfully; however, the truncation is an internal truncation so there was a concern 
about the stability of the construct. Since preliminry data showed that the Δ36 had data for 
having decrease stability in the trimeric form and was instead naturally occurring monomers, the 
Δ36 truncation was used to allow for more consistent results.  
 The wild type and mutants were expressed in LobSTR cells and were attempted to be 
purified by Ni-NTA affinity chromatography. However, the protein was not soluble and an extra 
step, the extraction with detergent, was necessary to extract the protein before purification. This 
is shown in both Figure 9 and 10. However, the protein was not extracted using typical extraction 
methods. This meant that detergents will need to be used to allow for better extraction, which is 
an important next step for this project. The protein is able to be expressed well in E. coli cells, 
but the extraction process is very difficult.  
 Other important next steps will be to run ligand binding assays, which will allow us to 
create comparisons between the S1R variants. This is of particular interest for the E102Q mutant 
as it has been connected to ALS, which means that this mutation naturally occurs in humans. 
This means that there is medical interest in how this mutation binds differently than the WT 
version. Another, important next step is to perform X-Ray crystallography to better understand 
the structure of these three proteins. This is of particular interest for the Δ36 truncation as it 
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shows a high tendency to form the monomer without an agonist present. Since this is the 
predicted form for the S1R to bind in, it would allow for the receptor to be used medicinally.   
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